Skip to content
Biodatica
Start free

Replimune, Inc.

Birmingham, Alabama

OncologyPhase IIIListed · REPL

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

5d agoTrial registeredJul 15, 2026Source filing (opens the source filing in a new tab)

Momentum

84no change

Momentum 84 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Jul 11, 2024

    Advanced Melanoma · RECRUITING · sponsor: Replimune, Inc. · VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

    ClinicalTrials.gov · NCT06264180 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    May 15, 2020

    Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer · ACTIVE_NOT_RECRUITING · sponsor: Replimune, Inc. · Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

    ClinicalTrials.gov · NCT04349436 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Oct 8, 2019

    Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Replimune, Inc. · Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

    ClinicalTrials.gov · NCT04050436 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Sep 20, 2017

    Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma · ACTIVE_NOT_RECRUITING · sponsor: Replimune, Inc. · Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

    ClinicalTrials.gov · NCT03767348 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources